D007140Chemicals & DrugsD12.644.541.500.650D12.776.124.486.485.680.650D12.776.124.790.651.680.650D12.776.377.715.548.680.650330.997478Immunoglobulin Fab FragmentsFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersontrue1Associate ProfessorAssociate ProfessorIoannisOikonomouIoannis Oikonomou350053Oikonomou, IoannisAssociate Professor16432380Oikonomou I, Shen BInflammatory bowel diseasesAre we moving forward in the biological treatment of Crohn's disease? Time will tell. Inflamm Bowel Dis. 2006 Feb; 12(2):147-9.Inflamm Bowel Dis2006-02-01T00:00:002006Are we moving forward in the biological treatment of Crohn's disease? Time will tell.LindaBaumLinda L Baum349173Baum, LindaProfessorTheodorePincusTheodore Pincus349493Pincus, TheodoreProfessor5Associate Professor4Professor3583316Baum LL, Johnson B, Berman S, Graham D, Mold CImmunologyC-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. Immunology. 1987 May; 61(1):93-9.Immunology1987-05-01T00:00:001987C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition.16915119Qureshi AI, Harris-Lane P, Kirmani JF, Janjua N, Divani AA, Mohammad YM, Suarez JI, Montgomery MONeurosurgeryIntra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study. Neurosurgery. 2006 Oct; 59(4):789-96; discussion 796-7.Neurosurgery2006-10-01T00:00:002006Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.21485024Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens KArthritis care & researchRAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken). 2011 Aug; 63(8):1142-9.Arthritis Care Res (Hoboken)2011-08-01T00:00:002011RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.0.4148460.01930963research area of0.4158950.01935844subject area forInternal MedicineRush University, Rush Medical Collegetrue1ProfessorProfessortrue1ProfessorProfessorInternal Medicine, Division of Rheumatology